[What do we think about selective estrogen receptor modulators?].
Cortet
B
B
D000367:Age Factors; D001943:Breast Neoplasms / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010919:Placebos; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000627:therapeutic use*; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000627:therapeutic use*; D012737:Sex Factors; D013997:Time Factors
D004965:Estrogen Antagonists; D010919:Placebos; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride